SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy. Due to its wide heterogeneity, PDAC acts aggressively and responds poorly to most chemotherapies, causing an urgent need for the development of new therapeutic strategies. Cell lines have been used...
Saved in:
Main Authors: | Enze Liu (Author), Zhuang Zhuang Zhang (Author), Xiaolin Cheng (Author), Xiaoqi Liu (Author), Lijun Cheng (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
by: Norihiro Sato, et al.
Published: (2016) -
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Published: (2021) -
Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
by: Jinlu Liu, et al.
Published: (2023) -
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
by: Alexander G. Raufi, et al.
Published: (2021) -
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
by: Rita Rebelo, et al.
Published: (2021)